Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10743497 | 0.83 | TSHR (0.30) | TSHR | |
| Adamantane SCHEMBL9651363 | 0.78 | TSHR (0.40) | TSHREPHX2 | |
| SCHEMBL4721541 | 0.78 | TSHR (0.40) | TSHREPHX2 | |
| SCHEMBL71132 | 0.78 | TSHR (0.40) | TSHREPHX2 | |
| SCHEMBL10285140 | 0.78 | TSHR (0.40) | TSHREPHX2 | |
| SCHEMBL14791313 | 0.78 | TSHR (0.40) | TSHREPHX2 | |
| SCHEMBL6315184 | 0.75 | TSHR (0.39) | TSHREPHX2 | |
| SCHEMBL3137075 | 0.75 | MEN1 (0.33) | — | |
| SCHEMBL1238943 | 0.73 | HSD11B1 (0.32) | EPHX2 | |
| Ethylene SCHEMBL1617394 | 0.73 | TSHR (0.37) | TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099218-A1 | MECHANOCALORIC METHOD | SUMITOMO CHEMICAL CO., LTD (JP) | 2026-05-15 | — | — | WO | claimed |
| US-5576355-A | INHIBITING HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS | MOBIL OIL CORP. (US) | 1996-11-19 | — | — | US | claimed |
| EP-0706384-A1 | DIAMONDOID DERIVATIVES FOR PHARMACEUTICAL USE | MOBIL OIL CORPORATION (US) | 1996-04-17 | — | — | EP | claimed |
| WO-1994028885-A1 | DIAMONDOID DERIVATIVES FOR PHARMACEUTICAL USE | MOBIL OIL CORPORATION (US) | 1994-12-22 | — | — | WO | claimed |
| US-5298666-A | Synthesis of adamantane-2,4-dione | MOBIL OIL CORPORATION (US) | 1994-03-29 | — | — | US | claimed |
| WO-2026099218-A1 | MECHANOCALORIC METHOD | SUMITOMO CHEMICAL CO., LTD (JP) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026099218-A1 | MECHANOCALORIC METHOD | SUMITOMO CHEMICAL CO., LTD (JP) | 2026-05-15 | — | — | WO | disclosed |
| US-20200181192-A1 | DISULFIDE BIOCONJUGATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-06-11 | — | — | US | disclosed |
| WO-2018201000-A1 | DISULFIDE BIOCONJUGATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-01 | — | — | WO | disclosed |
| US-7371778-B2 | Spiro and dispiro 1,2,4-trioxolane antimalarials | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2008-05-13 | — | — | US | disclosed |
| US-20050256185-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2005-11-17 | — | — | US | disclosed |
| US-5576355-A | INHIBITING HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS | MOBIL OIL CORP. (US) | 1996-11-19 | — | — | US | disclosed |
| US-5410092-A | Synthesis of adamantane-2,4-dione | MOBIL OIL CORPORATION (US) | 1995-04-25 | — | — | US | disclosed |
| US-5410092-A | Synthesis of adamantane-2,4-dione | MOBIL OIL CORPORATION (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1994028885-A1 | DIAMONDOID DERIVATIVES FOR PHARMACEUTICAL USE | MOBIL OIL CORPORATION (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5298666-A | Synthesis of adamantane-2,4-dione | MOBIL OIL CORPORATION (US) | 1994-03-29 | — | — | US | disclosed |
| US-5298666-A | Synthesis of adamantane-2,4-dione | MOBIL OIL CORPORATION (US) | 1994-03-29 | — | — | US | disclosed |
| EP-0554244-A1 | ADAMANTANE POLYMERIC COMPOSITIONS | MOBIL OIL CORPORATION (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1992007018-A1 | ADAMANTANE POLYMERIC COMPOSITIONS | MOBIL OIL CORPORATION (US) | 1992-04-30 | — | — | WO | disclosed |
| US-5053434-A | Diamondoid polymeric compositions | MOBIL OIL CORPORATION (US) | 1991-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181192-A1 | DISULFIDE BIOCONJUGATION | P4HB, PDIA6, PDIA5 | TSHR 1370/4885EPHX2 2513/4885 |
| US-20050256185-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | DHODH, THPO, SQLE | TSHR 2097/4885EPHX2 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.